
Marcus Today Pre-Market Podcast – Friday 16th February
US stocks closed higher on Thursday as retail sales data disappointed, fuelling expectations of potential interest rate cuts by the Fed in the coming months. The S&P 500 rose by 0.58%, the NASDAQ by 0...
15 Feb 202416min

Marcus Today End of Day Podcast – Thursday 15th February
ASX 200 made up yesterday’s losses closing up 58 points to 7601 (+0.8%). First ‘Super Thursday’ of results. BHP lost 1.7% on a huge write-down on nickel assets (more like liabilities) and Samarco issu...
15 Feb 202419min

Marcus Today Pre-Market Podcast – Thursday 15th February
The 500-stock index advanced 0.6%, while the Nasdaq Composite climbed 0.9%. The Dow Jones Industrial Average added 82 points, or 0.2%. Six of the seven Magnificent Seven tech stocks were higher, thou...
14 Feb 202417min

Marcus Today End of Day Podcast – Wednesday 14th February
ASX 200 fell 56 points bouncing off 7500 to close at 7538 (-0.7%). Results and broker talk dominated again with a negative lead from Wall Street colouring the landscape. Banks under pressure following...
14 Feb 202416min

Marcus Today Pre-Market Podcast – Wednesday 14th February
The Dow Jones Industrial Average lost 524.63 points, or 1.35%, to close at 38,272.75 in its worst session since March 2023 on a percentage basis. At its lows, the 30-stock index sunk 757.52 points, or...
13 Feb 202415min

Marcus Today End of Day Podcast – Tuesday 13th February
ASX 200 slipped 11 points to close at 7606 (-0.2%) as results dominated. CSL and MQG were a little disappointing but off lows, JHX dropped 8.5% on a slightly bearish update for Q3, and SEK also suffer...
13 Feb 202414min

Marcus Today Pre-Market Podcast – Tuesday 13th February
Stocks in the US remained relatively steady, with all three major indices holding near record highs ahead of the upcoming US CPI release. The NASDAQ briefly surpassed its previous closing high from No...
12 Feb 202414min

Marcus Today End of Day Podcast – Monday 12th February
ASX 200 falls 30 points to 7615 (0.4%) as a CSL drug trial fails. A Phase III trial for CSL saw the stock down 4.8% with RMD off 1.4%. Industrials solid with good results from JBH lifting the retail s...
12 Feb 202411min



















